Summary
Development of a thermostable microneedle patch for the delivery of an AgTRIOVx mRNA-LNP malaria vaccine, aimed at improving vaccine deployment in resource-poor countries.
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
US · IL
NIH
grant
awarded
#nih-5R41AI184218-02
What they want
The project focuses on developing novel dissolvable microneedle patches (MNPs) to administer an AgTRIO mRNA-LNP formulation. The goal is to produce an AgTRIOVx MNP that provides protection against malaria in a mouse model, serving as preparation for future pre-clinical and human clinical studies. The MNPs are designed to be self-applied, less painful than injections, produce no sharps waste, have a long shelf life (up to six months at room temperature), and be scalable.
Deliverables
- Novel AgTRIOVx MNP that protects against malaria in a mouse model
Technical requirements
- Dissolvable microneedle patches (MNPs)
- AgTRIO mRNA-LNP formulation
- Thermostable (long-term shelf life up to six months at room temperature)
Risks & flags
- This appears to be an abstract describing an awarded research grant from NIH RePORTER, not an open procurement opportunity (RFP/IFB/RFQ). As such, many standard procurement fields (e.g., response due date, submission format, evaluation criteria, set-asides) are not applicable or present.
Market context
inferred from NAICSProfessional, Scientific & Technical Services
NAICS 541714
- US market size
- $2.0T
- Typical award
- $25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP
Sector-level estimate — full code lookup not yet in catalog.
